ADAM9 and pancreatic neoplasm: Furthermore, decreased miR-126 expression has been previously linked with pancreatic cancer.24, 32 Existing literature has suggested that ADAM9 is overexpressed during the progression of cancer in addition to indicating that silencing ADAM9 could promote both the radio-sensitivity and chemosensitivity of cancer cells to therapeutic drugs.33